Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients

Bone Marrow Transplantation
D O'SheaA Rahemtulla

Abstract

High-dose therapy with autologous stem cell therapy (ASCT) has become the treatment of choice for eligible patients with myeloma. We analysed retrospectively the prognostic influence of pre-transplant characteristics and transplant modalities on response and survival in 211 myeloma patients who were transplanted in our centre between 1994 and 2004. All patients received peripheral blood stem cell support after conditioning with melphalan alone (183 patients), or melphalan and total blood irradiation (28 patients). We evaluated the influence of age, type of multiple myeloma, status prior and post ASCT, previous treatment regimens, time of ASCT from diagnosis, year of autograft, dose of re-infused CD34(+) cells, plasma cell infiltration and beta2-microglobulin at diagnosis on overall survival (OS) and event-free survival (EFS) to define patients with better prognosis. Median OS and EFS from transplantation were 50.9 and 20.1 months, respectively. Median OS from diagnosis was 68.8 months. Transplant-related mortality was 1.4%. Lower beta2-microglobulin levels, achievement of complete remission (CR) post transplant and lower plasma cell infiltration at diagnosis and transplant correlated with longer EFS and OS, whereas CR at transp...Continue Reading

References

Aug 1, 1994·British Journal of Haematology·M A DimopoulosR Alexanian
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D H VesoleB Barlogie
Oct 2, 2001·CA: a Cancer Journal for Clinicians·R T GreenleeM Thun
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Dec 4, 2003·Bone Marrow Transplantation·D E ReeceD H Vesole
Mar 24, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C MorrisUNKNOWN Chronic Leukaemia Working Party Myeloma Subcommittee, European Group for Blood and Marrow Transplantation

❮ Previous
Next ❯

Citations

Jan 14, 2009·Bone Marrow Transplantation·W BensingerJ M McCarty
Dec 24, 2010·Nature Reviews. Clinical Oncology·Jacob Laubach, Paul Richardson
Jun 18, 2009·Current Opinion in Oncology·Shaji Kumar
Dec 17, 2009·The Cancer Journal·Ajay NookaSagar Lonial
Sep 13, 2014·Hematology/oncology Clinics of North America·Heather Landau, Sergio Giralt
Oct 1, 2011·Leukemia & Lymphoma·Valdas PeceliunasLaimonas Griskevicius
Feb 6, 2009·Leukemia & Lymphoma·Hang QuachH Miles Prince
Jul 1, 2008·Expert Review of Anticancer Therapy·Paul G RichardsonKenneth C Anderson
Aug 24, 2007·Expert Opinion on Investigational Drugs·Pellegrino Musto, Fiorella D'Auria
Dec 7, 2010·Best Practice & Research. Clinical Haematology·John F DiPersio
Oct 13, 2007·Clinical Lymphoma & Myeloma·Sundar Jagannath
Jul 22, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Manish SharmaParameswaran Hari
Jul 13, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mark KorthalsRoland Fenk
May 12, 2015·Bone Marrow Transplantation·T M WildesG Colditz
Aug 28, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ivana N M MicallefShaji Kumar
Oct 23, 2012·Clinical Lymphoma, Myeloma & Leukemia·Lalit KumarOmdutt Sharma
Mar 17, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jin Seok KimUNKNOWN Korean Multiple Myeloma Working Party
Jun 5, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Koji SasakiMuzaffar H Qazilbash
Apr 5, 2011·Hematology/oncology and Stem Cell Therapy·Jean El CheikhDidier Blaise
Jun 3, 2015·Stem Cells Translational Medicine·Natasha AliMohammad Usman Shaikh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.